5Vote!
Fool.com (Free subscription) | 11/23/2009
... analysts do.More and more top-performing CAPS members have been turning to the bullish side of Allos Therapeutics(Nasdaq: over the past year -- enough, in fact, to take it all the way from a lowly two-star to the highest possible . A total of 245 members have given their opinion on the drug developer, with many of them offering analysis and commentary explaining the recent optimism.The biopharmaceutical...
4Vote!
Business Wire (Free subscription) | 11/11/2009
WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that abstracts from studies of FOLOTYN™ (pralatrexate injection) were accepted for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held at the Ernest N. Morial Convention Center in New Orleans, La., from December 5-8, 2009. Four poster presentations will...
4Vote!
The Earth Times Online Newspaper (Free subscription) | 11/10/2009
WESTMINSTER, Colo. - Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that management will present at two upcoming conferences: the Lazard Capital Markets 6th Annual
4Vote!
Business Wire (Free subscription) | 11/10/2009
WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that management will present at two upcoming conferences: the Lazard Capital Markets 6th Annual Healthcare Conference and the Windhover Therapeutic Area Partnerships event, where the...
6Vote!
SeekingAlpha.com (Free subscription) | 11/04/2009
Allos Therapeutics, Inc., ( ALTH ) Q3 2009 Earnings Call November 3, 2009 4:30 pm ET Complete Story »
4Vote!
Business Wire (Free subscription) | 11/03/2009
WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) today reported results for the third quarter of 2009. For the three months ended September 30, 2009, the Company reported a net loss of $18.7 million, or ($0.21) per share. This compares to a net loss of $13.2 million, or ($0.16) per share, for the third quarter of 2008. For the nine months ended September 30, 2009,...
4Vote!
bizjournals (Free subscription) | 11/04/2009
Colorado biotech firm Allos Therapeutics Inc. posted a bigger third-quarter loss, citing higher administrative and marketing costs as it gears up to sell its newly approved cancer drug Folotyn. (ALTH)
5Vote!
The Denver Business Journal (Free subscription) | 11/04/2009
Colorado biotech firm Allos Therapeutics Inc. posted a bigger third-quarter loss, citing higher administrative and marketing costs as it gears up to sell its newly approved cancer drug Folotyn. (ALTH)
4Vote!
Business Wire (Free subscription) | 10/26/2009
WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that Company management will provide a corporate update and review of the third quarter 2009 results via webcast and conference call on Tuesday, November 3, 2009, at 4:30 p.m. ET. To...
5Vote!
The Street (Free subscription) | 11/23/2009
NEW YORK (TheStreet) -- Allos Therapeutics is the best speculative bet in the sector. Watch this video for the safest and biggest growth stock to add to your portfolio.
3Vote!
Medical News Today (Free subscription) | 11/24/2009
... for Non-Hodgkin's Lymphomas that incorporated the FDA approval of pralatrexate (Folotyn(TM), Allos Therapeutics, Inc.) for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).The NCCN Clinical Practice Guidelines in Oncology(TM) are developed and updated through an evidence-based process with explicit review of the scientific evidence integrated with expert judgment...
4Vote!
Market Wire (Free subscription) | 11/11/2009
NEW DELHI, INDIA (MARKET WIRE) Analyst Choice has combined some of the best financial and technical minds worldwide to bring you an array of free quality equity research and reporting. Today we have begun in-depth reporting on our website evaluating the current market condition of EarthLink Inc. (NASDAQ: ELNK), News Corp. (NASDAQ: NWSA), NetApp Inc. (NASDAQ: NTAP), Allos Therapeutics Inc. (NASDAQ:...
